小脑顶核电刺激对脑微出血患者认知功能的影响

Effect of cerebellar fastigial nucleus stimulation on cognitive function of patients with cerebral microbleeds

摘要:

目的观察小脑顶核电刺激（FNS）对脑微出血（CMB）患者认知功能的影响。方法35例CMB患者随机分为观察组及对照组。两组都给予内科常规药物治疗，观察组还接受FNS 治疗。采用蒙特利尔认知评估量表（MoCA）于治疗前、治疗15 d 后对两组患者进行认知功能测评，并用MRI 磁敏感加权成像对CMB 病灶进行检查。结果①FNS 治疗后与治疗前观察组CMB 病灶数目的比较差异无统计学意义（P >0.05）。观察组治疗后CMB 病灶数目与对照组治疗后的数目比较差异无统计学意义（P >0.05）；②药物治疗前、后对照组MoCA 8个分项认知功能评分及总评分的比较差异无统计学意义（ P>0.05）。观察组FNS 治疗后MoCA 8个分项认知功能评分及总评分比治疗前的评分有提高（P <0.05）。观察组治疗后MoCA 8个分项认知功能评分及总评分比对照组治疗后的评分有提高（P <0.05）。结论FNS 可改善CMB 患者的认知功能，且安全，其有可能为CMB认知功能障碍患者提供1 种辅助治疗手段。

Abstract:

Objective To observe the effect of cerebellar fastigial nucleus stimulation (FNS) on the cognitive function of patients with cerebral microbleeds (CMB). Methods A total of 35 CMB cases were randomly divided into observation group and control group. All the patients were given routine medical treatment, and the observation group was further treated with FNS. Montreal cognitive assessment (MoCA) scale was used to evaluate cognitive function of all the patients before and after 15 days' treatment, and MRI susceptibility-weighted imaging was used to detect CMB lesions. Results Before and after FNS treatment,there was no significant difference in the amount of CMB lesions in the observation group (P > 0.05). After the treatment, there was no significant difference in the amount of CMB lesions between the observation group and the control group (P > 0.05); there were no significant differences in the scores of 8 cognitive sub-items in MoCA scale and the total score in the control group before and after medical treatment (P > 0.05). The scores of 8 cognitive sub-items in MoCA scale and the total score in the observation group after FNS treatment were significantly higher than those before FNS treatment (P < 0.05). Meanwhile, the scores of 8 cognitive subitems in MoCA scale and the total score in the observation group after the treatment were significantly higher than those in the control group (P < 0.05). Conclusions FNS can improve the cognitive function in patients with CMB as a safe treatment, which may provide an auxiliary one for patients with CMB cognitive impairment.